Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05202418
Other study ID # IRB00085974
Secondary ID 5K23DK122115-021
Status Completed
Phase N/A
First received
Last updated
Start date February 27, 2022
Est. completion date January 13, 2024

Study information

Verified date March 2024
Source Emory University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, assessment-based study to examine the relationship between psychophysiological functioning and psychological symptoms in youth newly diagnosed with inflammatory bowel disease (IBD) compared to healthy controls.


Description:

Detailed Description: Similar to other chronic stressors, diagnosis with a chronic illness places youth at risk of adverse psychosocial outcomes. Inflammatory bowel diseases (IBD), Crohn's disease, ulcerative colitis, and indeterminate colitis are chronic, immune-mediated diseases of the gastrointestinal tract characterized by unpredictable remissions of disease activity followed by relapses of symptoms. Although some research has found higher levels of disease activity to relate to greater depressive symptoms, the overall relationship between disease activity and emotional functioning has been mixed, suggesting that additional individual differences need to be considered in addition to illness-related factors when predicting emotional outcomes. Increased risk for developing anxiety disorders and depression has been documented in youth with IBD. Individual differences in physiological reactivity may affect patients' risk for developing psychosocial difficulties within the context of chronic stress. Additional risk factors for the development of psychosocial difficulties need to be identified to identify moderators of outcomes above and beyond disease activity. Individual differences in physiological reactivity may affect patients' risk for developing psychosocial difficulties within the context of chronic stress. Physiological reactivity, which broadly refers to bodily reactions in response to a stressor, varies with regards to intensity and threshold for activation between individuals. In youth affected by non-medical chronic stress (e.g., family conflict, trauma history), measures of autonomic dysfunction have been used to explain why some individuals have worse psychological and physical outcomes compared to others exposed to similar levels of chronic stress. Results support autonomic dysfunction as a vulnerability factor for adjustment problems within the context of chronic environmental stress. The aim of the current study is to test whether differences in psychophysiological reactivity serve as risk factors in the relationship between clinical disease activity in youth newly diagnosed with IBD and psychosocial adjustment problems. The relationship between psychophysiological reactivity and psychosocial adjustment problems in youth with IBD will be compared to healthy controls. Youth participants with IBD will be enrolled in a coping skills treatment to test the effectiveness of a cognitive-behavioral intervention including biofeedback to reduce anxiety and depression and disease symptoms. The research team will conduct a pilot intervention targeting autonomic dysfunction through biofeedback enhanced coping skills treatment delivered virtually over 6-sessions.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date January 13, 2024
Est. primary completion date January 13, 2024
Accepts healthy volunteers No
Gender All
Age group 13 Years to 18 Years
Eligibility Inclusion Criteria: - Diagnosed with biopsy-confirmed IBD - Ages 13 through 18 years inclusive - English fluency for parent and child participants. - Accompanied by at least 1 parent/guardian who is willing to participate - Positive depression or anxiety symptom screen using the patient health questionnaire (PHQ-9) or Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric Anxiety measures Exclusion Criteria: - Previous diagnosis of intellectual disability - Autism spectrum disorder. - Parent is unwilling to participate.

Study Design


Intervention

Behavioral:
Biofeedback Enhanced Treatment
The intervention involves biofeedback enhanced cognitive behaviorally based coping skills treatment. Treatment will consist of a 6-visit group intervention conducted online, via Emory zoom. Groups will include 5-8 patients each. Sessions will include brief, daily homework to facilitate mastery that is developmentally tailored to youth (e.g., practice skills with support from phone or tablet apps). Groups will meet approximately every week for 6 weeks. Advanced Ph.D. students in clinical psychology and Principal Investigator will deliver the treatment protocol. Participants will complete questionnaires before and after each session to measure autonomic reactivity, lifetime stress, depression, anxiety in response to stress induction, and coping strategies.

Locations

Country Name City State
United States Atlanta Metropolitan Area Atlanta Georgia
United States Children's Healthcare of Atlanta Atlanta Georgia
United States Emory Children's Center Building Atlanta Georgia

Sponsors (3)

Lead Sponsor Collaborator
Emory University Children's Healthcare of Atlanta, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in the retention rate Measures including consent rates, completion/retention rates will be summarized using counts and percentages or means and standard deviations, as appropriate. Baseline, 6 weeks (End of treatment), and 2 months post treatment
Primary Changes in treatment satisfaction Treatment satisfaction ratings will be summarized using counts and percentages or means and standard deviations, as appropriate. 6 weeks (End of treatment) and 2 months post treatment
Secondary Changes in clinical scores (depression) will be summarized within groups at each study time-point. Children's Depression Inventory 2 (CDI-2). The CDI 2 is a child-report measure of physiological, behavioral, and emotional symptoms of depression. The full-length CDI 2: Self-Report (CDI 2:SR) is a 28-item assessment that yields a Total Score, two-scale scores, and four subscale scores. For each item, the respondent is presented with three choices that correspond to three levels of symptomatology: 0 (absence of symptoms), 1 (mild or probable symptom), or 2 (definite symptom). A total score of = 60 may indicate concerns for depression. An estimation of the mediation effect will be calculated using the difference in the regression coefficients (ß1-ß2) baseline, 6 weeks (End of treatment), and 2 months post treatment
Secondary Changes in scores (anxiety disorders) will be summarized within groups at each study time-point. The Screen for Child Anxiety Related Disorders (SCARED). The SCARED is a 41-item inventory rated on a 3-point Likert-type scale used to screen for anxiety disorders. The SCARED offers a Total score as well as five symptom domains: panic/somatic, separation anxiety, generalized anxiety, social anxiety, and school phobia. The SCARED is a screening measure and not a diagnostic of anxiety disorders. That being said, the authors provide cut scores for each scored domain that may be indicative of an anxiety disorder. A total score of = 25 may indicate an anxiety disorder, and for each of the subscales, a score of 7 may indicate Panic Disorder, a score of 9 may indicate Generalized anxiety, a score of 8 may indicate Social Phobia, and a score of 3 may indicate significant school avoidance. An estimation of the mediation effect will be calculated using the difference in the regression coefficients (ß1-ß2). baseline, 6 weeks (End of treatment), and 2 months post treatment
Secondary Changes in clinical scores (clinical symptoms) will be summarized within groups at each study time-point. Self-report of disease activity using the Children's Somatic Symptoms Inventory- 24 (CSSI), GI Module will be collected. The GI symptom subscale includes items referring to nausea, constipation, diarrhea, abdominal pain, vomiting, feeling bloated, and food making you sick. The GI symptoms subscale has shown sensitivity to treatment. An estimation of the mediation effect will be calculated using the difference in the regression coefficients (ß1-ß2) baseline, 6 weeks (End of treatment), and 2 months post treatment
Secondary Changes in autonomic reactivity will be summarized within groups at each study time-point. Autonomic reactivity will be measured using Heart rate variability, measured using the Inner Balance system designed by HeartMath. Measures of heart rate variability will be taken before treatment, post-treatment, and follow-up. An estimation of the mediation effect will be calculated using the difference in the regression coefficients (ß1-ß2) baseline, 6 weeks (End of treatment), and 2 months post treatment
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04046913 - The ADDapt Diet in Reducing Crohn's Disease Inflammation N/A
Active, not recruiting NCT04989907 - A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
Recruiting NCT05316584 - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy N/A
Active, not recruiting NCT04990258 - A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
Completed NCT06216223 - Laser Versus Surgery in Anal Diseases in Inflammatory Bowel Patients N/A
Enrolling by invitation NCT06015789 - Self-care in Patients Affected by Inflammatory Bowel Disease and Caregivers' Contribution to Self-care
Recruiting NCT06065995 - StoMakker Mobile Application N/A
Recruiting NCT03282786 - Comparison of Carbon Dioxide (CO2) to Air Insufflation in Colonoscopy in Patients With Inflammatory Bowel Disease N/A
Recruiting NCT06002074 - SMART Program Impact on Quality of Life in Inflammatory Bowel Diseases N/A
Recruiting NCT04960826 - Study of an Environmental Risk Factor in Crohn's Disease
Recruiting NCT05413941 - Internet-based Cognitive Behavioral Therapy in Inflammatory Bowel Disease N/A
Completed NCT03668249 - A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
Completed NCT00721812 - A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686 Phase 1
Recruiting NCT05809999 - IBD Neoplasia Surveillance RCT N/A
Recruiting NCT04138225 - The Ecological Role of Yeasts in the Human Gut
Recruiting NCT04991324 - Cholecalciferol Comedication in IBD - the 5C-study Phase 3
Completed NCT03173144 - Chronic Inflammatory Disease, Lifestyle and Treatment Response
Not yet recruiting NCT05043818 - A Clinical Study on the Screening of Intestinal Biomarkers in IBD Patients With Depression
Recruiting NCT03042091 - Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery Early Phase 1
Not yet recruiting NCT02858557 - The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases N/A